Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Anidulafungin
See also Echinocandins
General information
Anidulafungin, an echinocandin, is an antifungal drug that acts by inhibiting β(1,3)- d -glucan synthase, which regulates the formation of β(1,3)- d -glucan, a major component of fungal cell walls [ ]. Its main adverse effect is hepatotoxicity with altered serum aminotransferases [ ].
Drug studies
Observational studies
The safety and efficacy of intravenous anidulafungin 50, 75, or 100 mg/day has been investigated in 123 patients, 68 evaluable, with invasive candidiasis, including candidemia [ ]. A total of eligible patients were randomized to one of three regimens. Adverse events considered to be related to treatment were reported by under 5% of patients in each dosage group. The most common events were hypotension, vomiting, constipation, nausea, and pyrexia. Three serious adverse events were reported as either probably or possibly related to treatment (neutropenic fever, n = 1; seizures, n = 2).
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here